Fulcrum Therapeutics’ Experimental Drug Fails in Muscle Disorder Study
In a significant setback, Fulcrum Therapeutics, a leading pharmaceutical company, announced that its experimental drug, losmapimod, failed to meet the primary goal in a late-stage study aimed at treating a type of muscle disorder known as facioscapulohumeral muscular dystrophy (FSHD).
The study involved 260 patients with FSHD, who were randomly assigned to receive either the therapy or a placebo for 48 weeks. The primary endpoint was to assess the improvement in shoulder and proximal arm mobility, a measure of shoulder and proximal arm mobility. However, at the end of the treatment period, patients who received the drug did not show any improvement in these measures, failing to meet the main goal of the study.
The study also failed to achieve statistical significance on any of its secondary goals. In light of these results, Fulcrum Therapeutics has decided to suspend testing of losmapimod in FSHD patients.
Facioscapulohumeral muscular dystrophy is a genetic disorder characterized by muscle weakness and wasting in the face, shoulder blades, and upper arms. According to the Muscle Dystrophy Association, the estimated prevalence of the disease is about 4 cases per 100,000 individuals.
The company’s shares fell nearly 70% before the market close, reflecting the negative impact of these results on the stock market.
Published on Sep 13, 2024 at 03:10 PM IST
Join the community of 2M+ industry professionals and subscribe to our newsletter to get the latest insights and analysis.
Reference : https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/fulcrum-stock-slumps-after-muscle-disorder-drug-fails-in-late-stage-study/113321020
